
aug pm et
summari engag discoveri develop commerci treatment
infect respiratori disord cardiovascular condit cancer
price-to-earnings oper ep
risk assess reflect gilead abil increas
domin hiv market share off-set slow hepat
 market see opportun oncolog emerg
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul stock trade
see sale declin
follow declin lower
sale hepat hcv drug lower
price shorter treatment durat
hepat hcv patient increas
competit see hcv sale
billion billion hiv
antivir sale rose billion
driven tenofovir alafenamid taf -base
drug includ genvoya descovi odefsey
biktarvi see solid increas
octob acquir kite pharma
expand presenc cell
gene-therapi yescarta becam first
adult non-hodgkin lymphoma
fail chemotherapi second
fda-approv gene therapi view
approv posit yet anticip slow
ramp due complic process
potenti sever side effect yescarta
price
see ep
earn
peak due success
sovaldi harvoni
although anticip continu signific
declin hcv sale believ share
trade forward ep
estim slightli peer
billion cash invest june
provid signific flexibl
capit deploy also encourag
growth hiv antivir
sever compound treat nash includ
selonsertib current phase
trial gs- phase ii
trial recent posit result
within inflamm partner
galapago began phase trial filgotinib
rheumatoid arthriti ulcer coliti
crohn diseas hcv believ
mavyret market share
 year-end aid
lower price point
risk recommend target price
includ larger-than-expect declin hcv
sale pipelin failur
target price
peer account declin sale
balanc pipelin potenti
continu market leadership hiv
oct ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview primari area focu includ human immunodefici
viru hiv liver diseas chronic hepat viru hcv infect chronic hepat viru
hbv infect oncolog inflamm seriou cardiovascular respiratori condit
oper approxim countri world-wide howev octob made signific
effort expand oncolog franchis acquisit
billion acquisit expand presenc cell therapi field octob kite
gene-therapi yescarta becam first fda-approv chimer antigen receptor cell therapi
approv yescarta treat adult non-hodgkin lymphoma fail chemotherapi time
second fda-approv gene therapi howev anticip slow ramp due
complic process potenti sever side effect yescarta price first
liver diseas area compani receiv approv food drug administr
fda sovaldi sofosbuvir decemb sovaldi cure rate hepat
week regimen drug quickli becam fastest grow drug histori first full year
sale sovaldi billion decemb expand hcv franchis approv
harvoni first once-daili singl tablet regimen treatment hcv genotyp infect adult
harvoni combin inhibitor ledipasvir nucleotid analog polymeras inhibitor sofosbuvir
sinc also receiv approv two addit hcv drug epclusa vosevi howev sale
hcv product start declin peak due competit well declin
patient pool sinc hcv product cure rate
compani evalu simtuzumab nonalcohol steatohepat nash phase clinic trial
decemb also enter agreement phenex pharmaceut ag phenex
compani acquir phenex farnesoid receptor fxr program consist small molecul
fxr agonist treatment liver diseas includ nash
hiv area stribild oral formul dose day treatment infect
treatment-na adult stribild compani third complet singl tablet regimen treatment
hiv fixed-dos combin antiretrovir medic vitekta tybost viread emtriva
emtricitabin stribild approv fda european commiss
atripla oral formul dose day treatment hiv infect adult atripla
compani first singl tablet regimen hiv intend therapi combin
antiretrovir fixed-dos combin compani antiretrovir medic viread
emtriva bristol-my squibb non-nucleosid revers transcriptas inhibitor sustiva efavirenz
truvada emtricitabin tenofovir disoproxil fumar oral formul dose day part
combin therapi treat hiv infect adult fixed-dos combin compani
antiretrovir medic viread emtriva fda also approv truvada combin safer
sex practic reduc risk sexual acquir infect adult high risk strategi call
viread oral formul nucleotid analog revers transcriptas inhibitor dose day
part combin therapi treat hiv infect patient two year age older european
commiss approv use viread combin antiretrovir agent treatment
infect adolesc patient age approxim year nucleosid revers
transcriptas inhibitor resist toxic preclud use first-lin pediatr agent viread
also approv treatment chronic hbv
impact major develop decemb receiv fda approv sovaldi treat hcv
sovaldi cure rate hepat week regimen drug quickli becam
fastest grow drug histori first full year sale sovaldi billion octob
acquir kite pharma billion expand presenc cell therapi field
octob kite gene-therapi yescarta becam first fda-approv chimer antigen receptor
cell therapi approv yescarta treat adult non-hodgkin lymphoma fail
chemotherapi second fda-approv gene therapi view approv posit juli
presid ceo john milligan announc step end year mr milligan
ceo less year face challeng rapidli declin hcv product sale
howev encourag effort expand oncolog gene therapi primarili
last year acquisit kite pharmaceut
financi trend sale risen billion billion repres
three-year annual growth rate compound-annual-growth-rate howev sale declin annual sinc peak
billion follow success hcv drug sovaldi harvoni howev due
smaller new patient popul cure rate drug increas competit much
lower price point sale hcv franchis drop significantli sale
billion doubl follow sovaldi approv decemb adjust ep
risen repres three-year compound-annual-growth-rate howev ep peak
chairman board
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc juli technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
biotechnolog sub-industri next
month reflect favor prospect new
novel therapi reach commerci yet
anticip modest overal
sale growth mainli due forecast
mid-teen sale declin
biotech sale rose low singl
digit follow growth
follow robust growth period
compound annual growth
rate think sale growth
somewhat limit heighten focu high
drug price encourag view
strong period report
late-stag clinic result
accommod fda approv
fda approv new drug --
sinc record approv
howev fda approv
new drug significantli robust
new drug approv think mani
newly-approv drug signific
commerci prospect repres major
advanc therapi diseas
sclerosi cancer fda
approv first time gene-therapi drug
involv remov patient immun cell
genet alter alter
cell re-introduc patient
help fight cancer
expect wider adopt biomark research
genetic-target clinic studi help
late fda introduc breakthrough
therapi design intend speed
develop promis program expect
favor merger acquisit climat
larg pharmaceut firm move off-set
lost revenu expir drug patent
larg biotech bolster drug pipelin amid
larger scale acquisit
fda author govern biosimilar
drug approv set exclus
advanc modest rate next
sever year see improv
biosimilar approv introduc
march fda approv novarti
filgrastim biosimilar version
novarti began sell
biosimilar name zarxio septemb
april fda approv
inflectra manufactur celltrion
co-market inflectra
biosimilar johnson johnson
expect biosimilar sell modest price
discount gener pharmaceut
industri due higher clinic manufactur
market cost expect brand
drug retain signific market share due
lack interchang think
biosimilar may appeal new user
expect current user stabl
current treatment would like continu
refer drug howev note
prescript benefit manag health
insur exert influenc drug
prescript price
remov neupogen formulari
replac zarxio
 biotech index rose vs
rise year date
juli biotech index
rose vs rise
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra maintain buy opinion share gilead scienc inc
announc sign definit agreement acquir
kite pharma inc kite nr billion per share cash kite
leader emerg field cell therapi use patient immun
system fight cancer deal subject customari close condit
regulatori approv expect close see deal posit
give excit asset particularli car-t therapi fight cancer kite
lead product axicabtagen ciloleucel expect receiv fda approv
et cfra keep buy opinion share gilead scienc
rais target peer
forward ep estim ep vs
ahead estim rais ep estim sale
fell better expect robust hiv sale strong
uptak taf product anticip continu lower hepat sale
encourag new patient start rais sale guidanc
cash believ provid
signific financi flexibl capit deploy /jeffrey loo cfa
et cfra keep buy opinion share gilead scienc inc
keep target peer
ep estim ep vs ahead
estim product sale fell hepat hcv product sale
fell continu declin harvoni sovaldi partial
off-set epclusa sale higher hiv product sale anticip continu
lower sale hcv product particularli europ increas competit
lower new patient start lower ep estim
cash see increas capit deploy /jeffrey
analyst research note compani news
keep target below-p
forward ep estim see continu declin sale
ep vs ahead view much lower tax
rate rais ep estim util
tax rate sale fell narrow
forecast declin hiv product sale solid rise
robust uptak new product descovi genvoya biktarvi
odefsey yet sale hepat hcv franchis fell
increas competit lower new patient start announc
presid ceo john milligan step year end mr milligan
ceo less three year face challeng rapidli
declin hcv product sale yet encourag effort expand
oncolog gene therapi primarili last year acquisit
et cfra keep hold opinion share gilead scienc
lower target peer
ep estim lower ep estim
ep vs estim sale
declin partli due lower expect sale
hepat hcv drug franchis declin
forecast total sale hepat sale believ
competitor mavyret hepat drug taken market share
aid aggress price estim mavyret market
share end see
share gain countri well expect continu volatil hcv
sale next sever quarter believ price market share
stabil mid-year sale hiv hbv drug rose new
gene therapi drug yescarta modest sale expect slow ramp
due complex process /jeffrey loo cfa
et cfra lower opinion share gilead scienc inc
hold buy keep target
below-p ep estim set ep
ep vs view sale fell
expect antivir product sale includ hiv hepat
hbv hepat hcv drug vs strength hiv
hbv off-set continu declin hcv see continu declin hcv
product sale note strong uptak competit offer like take
market share guid sale mid
keep target well-below-p
forward ep estim ep vs
ahead view sale fell slower hepat sale
forecast encourag posit phase ii trial result
treat nonalcohol steatohepat nash recent
yescarta approv treat non-hodgkin lymphoma anticip slow ramp-up
yescarta need final train certif due
complic process still see blockbust potenti yescarta /jeffrey
et cfra keep buy opinion share gilead scienc
recent acquir kite pharma receiv fda approv
gene-therapi treatment yescarta treat adult non-hodgkin
lymphoma fail chemotherapi second gene therapi
approv fda view approv posit although
anticip slow ramp-up due complic process potenti sever
side-effect believ yescarta receiv approv indic
reach sale yescarta price
norvarti gene therapi treatment kymriah price /jeffrey loo
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
